Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.

Mustjoki S, Auvinen K, Kreutzman A, Rousselot P, Hernesniemi S, Melo T, Lahesmaa-Korpinen AM, Hautaniemi S, Bouchet S, Molimard M, Smykla R, Lee FY, Vakkila J, Jalkanen S, Salmi M, Porkka K.

Leukemia. 2013 Apr;27(4):914-24. doi: 10.1038/leu.2012.348. Epub 2012 Nov 29.

PMID:
23192016
2.

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.

Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinolli T, Liesveld J, Paquette R, Pinilla-Ibarz J, Rauhala A, Shah N, Simonsson B, Sinisalo M, Steegmann JL, Stenke L, Porkka K.

Leukemia. 2009 Aug;23(8):1398-405. doi: 10.1038/leu.2009.46. Epub 2009 Mar 19.

PMID:
19295545
3.

Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study.

Uchiyama T, Sato N, Narita M, Yamahira A, Iwabuchi M, Furukawa T, Sone H, Takahashi M.

Hematol Oncol. 2013 Sep;31(3):156-63. doi: 10.1002/hon.2034. Epub 2012 Oct 29.

PMID:
23108877
4.

Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy.

Rohon P, Porkka K, Mustjoki S.

Eur J Haematol. 2010 Nov;85(5):387-98. doi: 10.1111/j.1600-0609.2010.01501.x.

PMID:
20662899
5.

Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro.

Nerreter T, Distler E, Köchel C, Einsele H, Herr W, Seggewiss-Bernhardt R.

Exp Hematol. 2013 Jul;41(7):604-614.e4. doi: 10.1016/j.exphem.2013.02.013. Epub 2013 Mar 4.

PMID:
23466625
6.

Direct effect of dasatinib on signal transduction pathways associated with a rapid mobilization of cytotoxic lymphocytes.

Iriyama N, Hatta Y, Takei M.

Cancer Med. 2016 Nov;5(11):3223-3234. doi: 10.1002/cam4.925. Epub 2016 Oct 10.

7.

Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib.

Hayashi Y, Nakamae H, Katayama T, Nakane T, Koh H, Nakamae M, Hirose A, Hagihara K, Terada Y, Nakao Y, Hino M.

Leuk Lymphoma. 2012 Jun;53(6):1084-9. doi: 10.3109/10428194.2011.647017. Epub 2012 Jan 20.

PMID:
22211798
8.

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.

Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Müller A, Baumgartner C, Valent P, Augustin M, Till JH, Superti-Furga G.

Leukemia. 2009 Mar;23(3):477-85. doi: 10.1038/leu.2008.334. Epub 2008 Nov 27.

PMID:
19039322
9.

An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib.

Xing H, Liu T, Meng W, Gong Y.

Int J Lab Hematol. 2011 Apr;33(2):176-81. doi: 10.1111/j.1751-553X.2010.01267.x. Epub 2010 Oct 4.

PMID:
20942869
10.

Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.

Simara P, Stejskal S, Koutna I, Potesil D, Tesarova L, Potesilova M, Zdrahal Z, Mayer J.

Am J Hematol. 2013 May;88(5):385-93. doi: 10.1002/ajh.23419. Epub 2013 Mar 27.

11.

The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.

Gratacap MP, Martin V, Valéra MC, Allart S, Garcia C, Sié P, Recher C, Payrastre B.

Blood. 2009 Aug 27;114(9):1884-92. doi: 10.1182/blood-2009-02-205328. Epub 2009 Jun 3.

12.

Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.

Okabe S, Tauchi T, Ohyashiki K.

Clin Cancer Res. 2008 Oct 1;14(19):6181-6. doi: 10.1158/1078-0432.CCR-08-0461.

13.

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, Porkka K, Mustjoki S.

Blood. 2010 Aug 5;116(5):772-82. doi: 10.1182/blood-2009-12-256800. Epub 2010 Apr 22.

14.

Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.

Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP, Hayball JD.

Exp Hematol. 2009 Feb;37(2):256-65. doi: 10.1016/j.exphem.2008.09.013. Epub 2008 Dec 3.

PMID:
19056158
15.

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.

Masiello D, Gorospe G 3rd, Yang AS.

J Hematol Oncol. 2009 Nov 12;2:46. doi: 10.1186/1756-8722-2-46. Review.

16.

Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.

Tyler T.

Ann Pharmacother. 2009 May;43(5):920-7. doi: 10.1345/aph.1L570. Epub 2009 Mar 31. Review.

PMID:
19336654
17.

Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages.

Bellora F, Dondero A, Corrias MV, Casu B, Regis S, Caliendo F, Moretta A, Cazzola M, Elena C, Vinti L, Locatelli F, Bottino C, Castriconi R.

J Immunol. 2017 Aug 15;199(4):1516-1525. doi: 10.4049/jimmunol.1601695. Epub 2017 Jul 12.

PMID:
28701512
18.

A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.

Guérin A, Chen L, Wu EQ, Ponce de Leon D, Griffin JD.

Curr Med Res Opin. 2012 Jul;28(7):1155-62. doi: 10.1185/03007995.2012.705264. Epub 2012 Jun 28.

PMID:
22738777
19.

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.

Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F, Belanger C, Manley PW, Leroy C, Etienne G, Roche S, Pasquet JM.

Cancer Res. 2008 Dec 1;68(23):9809-16. doi: 10.1158/0008-5472.CAN-08-1008.

20.

Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line.

Okabe S, Tauchi T, Tanaka Y, Ohyashiki K.

J Hematol Oncol. 2011 Aug 2;4(1):32. doi: 10.1186/1756-8722-4-32.

Supplemental Content

Support Center